Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis
Author:
Open Access
- 1 January 2014
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (11) , 3025-32
Abstract
To investigate the potential of serum peptides as a diagnostic tool for hepatocellular carcinoma (HCC) with bone metastasis. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) was used to characterize the serum peptide profile of HCC patients with bone metastasis. Serum samples from 138 HCC patients (66 cases with and 72 cases without bone metastasis) were randomly assigned into a training set (n = 76) and a test set (n = 62). Differential serum peptides were examined using ClinProt magnetic bead-based purification followed by MALDI-TOF-MS. The sequences of differentially expressed serum peptides were identified using liquid chromatography-mass spectrometry. A diagnostic model was established using a learning algorithm of radial basis function neural network verified by a single blind trial. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic power of the established model. Ten peptide peaks were significantly different between HCC patients with or without bone metastasis (P < 0.001). Sequences of seven peptides with mass to charge ratios (m/z) of 1780.7, 1866.5, 2131.6, 2880.4, 1532.4, 2489.8, and 2234.3 were successfully identified. These seven peptides were derived from alpha-fetoprotein, prothrombin, serglycin, isoform 2 of inter-alpha-trypsin inhibitor heavy chain H4, isoform 1 of autophagy-related protein 16-2, and transthyretin and fibrinogen beta chains, respectively. The recognition rate and predictive power of a diagnostic model established on the basis of six significant peptides (m/z for these six peptides were 1535.4, 1780.7, 1866.5, 2131.6, 2880.4, and 2901.9) were 89.47% and 82.89%, respectively. The sensitivity and specificity of this model based upon a single blind trial were 85.29% and 85.71%, respectively. ROC analysis found that the AUC (area under the ROC curve) value was 0.911. Our study suggested that serum peptides may serve as a diagnosis tool for HCC bone metastasis.Keywords
This publication has 27 references indexed in Scilit:
- Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinomaWorld Journal of Gastroenterology, 2013
- Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinomaProteomics, 2006
- Differential exoprotease activities confer tumor-specific serum peptidome patternsJournal of Clinical Investigation, 2005
- Heat‐shock protein 27: A potential biomarker for hepatocellular carcinoma identified by serum proteome analysisProteomics, 2005
- CT Appearance of Bone Metastases Detected with FDG PET as Part of the Same PET/CT ExaminationRadiology, 2005
- Clinical features of hepatocellular carcinoma with extrahepatic metastasesJournal of Gastroenterology and Hepatology, 2005
- Direct Tandem Mass Spectrometry Reveals Limitations in Protein Profiling Experiments for Plasma Biomarker DiscoveryJournal of Proteome Research, 2005
- Alcohol and hepatocellular carcinomaGastroenterology, 2004
- Identifying Breast Cancer Patients at High Risk for Bone MetastasesJournal of Clinical Oncology, 2000
- Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate TreatmentNew England Journal of Medicine, 1998